Skip to main content
Top
Published in: Osteoporosis International 4/2014

Open Access 01-04-2014 | Case Report

Aseptic necrosis at multiple localisations in a lupus patient with lymphoma

Authors: A. Bazso, T. Bazso, P. Szodoray, G. Poor, E. Kiss

Published in: Osteoporosis International | Issue 4/2014

Login to get access

Abstract

Avascular or aseptic necrosis is a well-defined entity leading to the degradation of cellular elements of the bone. The pathogenesis of osteonecrosis (ON) is still unknown. There are two main types of ON: traumatic or non-traumatic. Several clinical entities could associate with ON, systemic diseases, environmental factors, pregnancy, systemic autoimmune or rheumatic diseases, thrombophilia, corticosteroid therapy, cytotoxic dugs, infections, metabolic and hematologic diseases, etc. Corticosteroids (CS) are still the most frequently used therapeutic options in the early phase and during flares of these diseases. Inflammatory cytokines and antibodies have been described to participate in the pathogenesis of ON. The infiltrative disorders of the bone marrow could also contribute to the development of ON. Hereby, we describe a female patient with NHL followed by SLE in whom ON has developed at least in two localisations. Lupus flare, long-term CS therapy, lymphoma relapse or the presence of antiphospholipid antibodies were excluded. Although the bi-localised ON could be contributed to immunologic factors or trauma, the exact aetiology in this case could not be elucidated.
Literature
1.
go back to reference Powell C, Chang C, Naguwa SM et al (2010) Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmune Rev 9:721–743CrossRef Powell C, Chang C, Naguwa SM et al (2010) Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmune Rev 9:721–743CrossRef
2.
go back to reference Seguro LP, Rosario C, Shoenfeld Y (2013) Long-term complications of past glucocorticoid use. Autoimmune Rev 12:629–632CrossRef Seguro LP, Rosario C, Shoenfeld Y (2013) Long-term complications of past glucocorticoid use. Autoimmune Rev 12:629–632CrossRef
3.
go back to reference Zonana Nacach A, Barr SG, Magder LS et al (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808PubMedCrossRef Zonana Nacach A, Barr SG, Magder LS et al (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808PubMedCrossRef
4.
go back to reference Assouline-Dayan Y, Chang C, Greenspa A et al (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94–124PubMedCrossRef Assouline-Dayan Y, Chang C, Greenspa A et al (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94–124PubMedCrossRef
5.
go back to reference Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythaematosus (SLE) and in non-SLE disorders; prevalence and clinical significance. Ann Intern Med 112:682–698PubMedCrossRef Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythaematosus (SLE) and in non-SLE disorders; prevalence and clinical significance. Ann Intern Med 112:682–698PubMedCrossRef
6.
go back to reference Rueda JC, Duque MA, Mantilla RD et al (2009) Osteonecrosis and antiphospholipid syndrome. J Clin Rheumatol 15:130–132PubMedCrossRef Rueda JC, Duque MA, Mantilla RD et al (2009) Osteonecrosis and antiphospholipid syndrome. J Clin Rheumatol 15:130–132PubMedCrossRef
7.
go back to reference Zonana-Nacach A, Jiménez-Balderas FJ (2004) Avascular necrosis of bone associated with primary antiphospholipid syndrome: case report and literature review. J Clin Rheumatol 10:214–217PubMedCrossRef Zonana-Nacach A, Jiménez-Balderas FJ (2004) Avascular necrosis of bone associated with primary antiphospholipid syndrome: case report and literature review. J Clin Rheumatol 10:214–217PubMedCrossRef
8.
go back to reference Houssiau FA, N’Zeusseu Toukap A, Depresseux G et al (1998) Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol 37:448–453PubMedCrossRef Houssiau FA, N’Zeusseu Toukap A, Depresseux G et al (1998) Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol 37:448–453PubMedCrossRef
9.
go back to reference Migliaresi S, Picillo U, Ambrosone L et al (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3:37–41PubMedCrossRef Migliaresi S, Picillo U, Ambrosone L et al (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3:37–41PubMedCrossRef
10.
go back to reference Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G, Kiss E (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus. Results from a single centre. Ann NY Acad Sci 1108:76–82PubMedCrossRef Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G, Kiss E (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus. Results from a single centre. Ann NY Acad Sci 1108:76–82PubMedCrossRef
11.
go back to reference Kiss E, Kovacs L, Szodoray P (2010) Malignancies in systemic lupus erythematosus. Autoimmun Rev 9(4):195–199PubMedCrossRef Kiss E, Kovacs L, Szodoray P (2010) Malignancies in systemic lupus erythematosus. Autoimmun Rev 9(4):195–199PubMedCrossRef
12.
go back to reference Sezer O (2009) Myeloma bone disease: recent advances in biology, diagnosis, and treatment. The Oncoogist 14:276–283CrossRef Sezer O (2009) Myeloma bone disease: recent advances in biology, diagnosis, and treatment. The Oncoogist 14:276–283CrossRef
13.
go back to reference Giuliani N, Bataille R, Mancini C et al (2003) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527–3533CrossRef Giuliani N, Bataille R, Mancini C et al (2003) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527–3533CrossRef
14.
go back to reference Heider U, Langelotz C, Jakob C et al (2003) Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436–1440PubMed Heider U, Langelotz C, Jakob C et al (2003) Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436–1440PubMed
15.
go back to reference Abe M, Hiura K, Wilde J et al (2002) Role of macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 100:2195–2202PubMed Abe M, Hiura K, Wilde J et al (2002) Role of macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 100:2195–2202PubMed
16.
go back to reference Sun LY, Zhang HY, Feng XB et al (2007) Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16:121–128PubMedCrossRef Sun LY, Zhang HY, Feng XB et al (2007) Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16:121–128PubMedCrossRef
17.
go back to reference Zannettino AC, Farrigia AN, Kortesidis A et al (2005) Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65:1700–1709PubMedCrossRef Zannettino AC, Farrigia AN, Kortesidis A et al (2005) Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65:1700–1709PubMedCrossRef
18.
go back to reference Toldi G, Szalay B, Bekő G, Bocskai M et al (2012) Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus. Biomarkers 17:758–763PubMedCrossRef Toldi G, Szalay B, Bekő G, Bocskai M et al (2012) Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus. Biomarkers 17:758–763PubMedCrossRef
19.
go back to reference Bernbeck B, Christaras A, Krauth K et al (2004) Bone marrow oedema and aseptic osteonecrosis in children and adolescents with acute lymphoblastic leukaemia or non-Hodgkin-lymphoma treated with hyperbaric-oxygen-therapy (HBO): an approach to cure?—BME/AON and hyperbaric oxygen therapy as a treatment modality. Klin Padiatr 216:370–378PubMedCrossRef Bernbeck B, Christaras A, Krauth K et al (2004) Bone marrow oedema and aseptic osteonecrosis in children and adolescents with acute lymphoblastic leukaemia or non-Hodgkin-lymphoma treated with hyperbaric-oxygen-therapy (HBO): an approach to cure?—BME/AON and hyperbaric oxygen therapy as a treatment modality. Klin Padiatr 216:370–378PubMedCrossRef
20.
go back to reference Heider U, Kaiser M, Mieth M et al (2009) Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 82:31–38PubMedCrossRef Heider U, Kaiser M, Mieth M et al (2009) Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 82:31–38PubMedCrossRef
21.
go back to reference Alcocer-Varela, Vidaller A, Llorente L (1988) Presence of an IL-3-producing suppressor T cell resistant to cyclosporin A in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol 73:424–429PubMedCentralPubMed Alcocer-Varela, Vidaller A, Llorente L (1988) Presence of an IL-3-producing suppressor T cell resistant to cyclosporin A in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol 73:424–429PubMedCentralPubMed
22.
go back to reference Paz Z, Tsokos GC (2013) New therapeutics in systemic lupus erythematosus. Curr Opin Rheumatol 25:297–303PubMedCrossRef Paz Z, Tsokos GC (2013) New therapeutics in systemic lupus erythematosus. Curr Opin Rheumatol 25:297–303PubMedCrossRef
23.
go back to reference Lee HC, Shah JJ, Orlowski RZ (2013) Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book 2013:302–306PubMedCentralCrossRef Lee HC, Shah JJ, Orlowski RZ (2013) Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book 2013:302–306PubMedCentralCrossRef
Metadata
Title
Aseptic necrosis at multiple localisations in a lupus patient with lymphoma
Authors
A. Bazso
T. Bazso
P. Szodoray
G. Poor
E. Kiss
Publication date
01-04-2014
Publisher
Springer London
Published in
Osteoporosis International / Issue 4/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2589-x

Other articles of this Issue 4/2014

Osteoporosis International 4/2014 Go to the issue